MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

NCT03932253 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

79

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor R\&D strategy adjustment

Conditions

Melanoma

Interventions

OTHER: FCN-159

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.